Compare Expensify Inc (EXFY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Novo Nordisk A/S — how do they compare? Expensify Inc trades at $1.79 (market cap $170.21M), while Novo Nordisk A/S trades at $51.39 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 1305.7× Expensify Inc's market cap, and Novo Nordisk A/S pays a 3.56% dividend while Expensify Inc pays none. Which is the better fit depends on your goals.
| EXFY | NVO | |
|---|---|---|
Market Cap | $170.21M | $222.24B |
Sector | Technology | Health |
52-Week High | $2.33 | $71.70 |
52-Week Low | $0.75 | $35.29 |
Enterprise Value | $109.24M | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $1.77, down 2.21% on the day, with a bullish technical signal from moving averages but mixed earnings history. Revenue for 2025 was $142.10M, but the company posted a net loss of -$21.39M, with negative profit margins and ROE. Recent news highlights product innovations like AI-powered expense automation and a $25M stock buyback program, indicating active management efforts to drive growth and shareholder value.
The outlook remains challenging due to persistent unprofitability, though positive cash flow from operations and strategic partnerships offer some stability. Investment opportunities hinge on successful execution of new AI and travel billing initiatives to improve margins. Key risks include intense competition in expense management software and the company's ability to achieve sustained profitability amid fluctuating revenues.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
